FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174842118> ?p ?o ?g. }

• W3174842118 endingPage "91" @default.
• W3174842118 startingPage "91" @default.
• W3174842118 abstract "We read the research article “A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness” by Ahmed S et al. with great interest. In this article, the authors describe the results of a randomized clinical trial conducted for the efficacy of ivermectin given in COVID-19 patients (Ahmed et al., 2021 FebAhmed S Karim MM Ross AG Hossain MS Clemens JD Sumiya MK et al.A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.Int J Infect Dis. 2021; 103 (Feb): 214-216Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar). The results of the study could be due to the dose of ivermectin used, which is lower than that needed for achieving optimal plasma concentration for antiviral activity. Previous evidence from preclinical and observational studies supports our premise. In a study demonstrating the in vitro antiviral activity of ivermectin, upon incubation of infected Vero/hSLAM cells with 5 μM ivermectin, there was an approximately 5000-fold reduction of viral RNA by 48 hours in ivermectin treated samples as compared with control. The IC50 of ivermectin was found to be approximately 2.5 μM. Ivermectin seems to act on IMPα/β1 and inhibits the nuclear translocation of SARS-CoV-2 (Caly et al., 2020Caly L Druce JD Catton MG Jans DA Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res. 2020; 178104787Crossref PubMed Scopus (1374) Google Scholar). Further in-silico studies are required to confirm this target of ivermectin in SARS-CoV-2. The concentrations of 2.5 and 5 μM correspond to plasma concentrations of 2190 and 4370 ng/mL, respectively. These concentrations are 50–100 times the peak plasma concentration achieved with the 200 μg/kg of ivermectin (the US Food and Drug Administration recommended dose for treatment of onchocerciasis) (Chaccour et al., 2017Chaccour C Hammann F Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.Malar J. 2017; 16: 161Crossref PubMed Scopus (63) Google Scholar). Even with a dose 10 times greater than this dose (i.e., 2000 μg/kg), a peak plasma concentration of only ~250 ng/mL has been achieved (Guzzo et al., 2017Guzzo CA Furtek CI Porras AG Chen C Tipping R Clineschmidt CM et al.Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.J Clin Pharmacol. 2017; 42: 1122-1133Crossref Scopus (270) Google Scholar). In a retrospective study, a single dose of 200 μg/kg of ivermectin was explored for its effect on patients with severe COVID-19. In congruence with this evidence, no improvement in microbiological and clinical outcomes was found in the ivermectin group compared with the control group (Camprubí et al., 2020Camprubí D Almuedo-Riera A Martí-Soler H Soriano A Hurtado JC Subirà C et al.Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.PLoS One. 2020; 15e0242184Crossref PubMed Scopus (44) Google Scholar). Similarly, in another randomized, double-blind clinical trial, ivermectin (administered at a dose of 300 μg/kg of body weight per day for 5 days) compared with placebo did not significantly improve the time to resolution of symptoms among adults with mild COVID-19 infection (López-Medina et al., 2021López-Medina E López P Hurtado IC Dávalos DM Ramirez O Martínez E et al.Effect of Ivermectin on Time to Resolution of Symptoms Among Adults with Mild COVID-19: A Randomized Clinical Trial.JAMA. 2021; 325: 1426-1435Crossref PubMed Scopus (224) Google Scholar). As per the World Health Organization's recommendations, the evidence is of very low certainty for the effects of ivermectin in reducing mortality, need for hospitalization, and reduction in time for clinical improvement in COVID-19 infection (WHO advises that ivermectin only be used to treat COVID-19 within clinical trials [Internet]WHO advises that ivermectin only be used to treat COVID-19 within clinical trials [Internet]. [cited 2021 May 13]. Available from: https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trialsGoogle Scholar). On the basis of the rationale above, any significant antiviral activity could not have been achieved with the dose used in the study and the resultant plasma concentration of the administered ivermectin. Thus, although ivermectin, in vitro, is a potent inhibitor of SARS-CoV-2 replication, in vivo, the plasma concentration required to achieve the antiviral effect far exceeds the therapeutically applicable dose. There was no conflict of interest There was no funding for this article" @default.
• W3174842118 created "2021-07-05" @default.
• W3174842118 creator A5001478992 @default.
• W3174842118 creator A5002472821 @default.
• W3174842118 date "2021-08-01" @default.
• W3174842118 modified "2023-10-10" @default.
• W3174842118 title "Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?" @default.
• W3174842118 cites W2012188043 @default.
• W3174842118 cites W2606413115 @default.
• W3174842118 cites W3014962324 @default.
• W3174842118 cites W3104739766 @default.
• W3174842118 cites W3107056972 @default.
• W3174842118 cites W3135420706 @default.
• W3174842118 cites W4253143966 @default.
• W3174842118 doi "https://doi.org/10.1016/j.ijid.2021.06.048" @default.
• W3174842118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8225296" @default.
• W3174842118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34175482" @default.
• W3174842118 hasPublicationYear "2021" @default.
• W3174842118 type Work @default.
• W3174842118 sameAs 3174842118 @default.
• W3174842118 citedByCount "3" @default.
• W3174842118 countsByYear W31748421182021 @default.
• W3174842118 countsByYear W31748421182022 @default.
• W3174842118 countsByYear W31748421182023 @default.
• W3174842118 crossrefType "journal-article" @default.
• W3174842118 hasAuthorship W3174842118A5001478992 @default.
• W3174842118 hasAuthorship W3174842118A5002472821 @default.
• W3174842118 hasBestOaLocation W31748421181 @default.
• W3174842118 hasConcept C126322002 @default.
• W3174842118 hasConcept C159047783 @default.
• W3174842118 hasConcept C2777499811 @default.
• W3174842118 hasConcept C2779134260 @default.
• W3174842118 hasConcept C3008058167 @default.
• W3174842118 hasConcept C42972112 @default.
• W3174842118 hasConcept C524204448 @default.
• W3174842118 hasConcept C71924100 @default.
• W3174842118 hasConcept C98274493 @default.
• W3174842118 hasConceptScore W3174842118C126322002 @default.
• W3174842118 hasConceptScore W3174842118C159047783 @default.
• W3174842118 hasConceptScore W3174842118C2777499811 @default.
• W3174842118 hasConceptScore W3174842118C2779134260 @default.
• W3174842118 hasConceptScore W3174842118C3008058167 @default.
• W3174842118 hasConceptScore W3174842118C42972112 @default.
• W3174842118 hasConceptScore W3174842118C524204448 @default.
• W3174842118 hasConceptScore W3174842118C71924100 @default.
• W3174842118 hasConceptScore W3174842118C98274493 @default.
• W3174842118 hasLocation W31748421181 @default.
• W3174842118 hasLocation W31748421182 @default.
• W3174842118 hasLocation W31748421183 @default.
• W3174842118 hasOpenAccess W3174842118 @default.
• W3174842118 hasPrimaryLocation W31748421181 @default.
• W3174842118 hasRelatedWork W1751241571 @default.
• W3174842118 hasRelatedWork W190931331 @default.
• W3174842118 hasRelatedWork W1987466624 @default.
• W3174842118 hasRelatedWork W2025964706 @default.
• W3174842118 hasRelatedWork W2109097527 @default.
• W3174842118 hasRelatedWork W2119974492 @default.
• W3174842118 hasRelatedWork W2132773307 @default.
• W3174842118 hasRelatedWork W2408674979 @default.
• W3174842118 hasRelatedWork W2419600336 @default.
• W3174842118 hasRelatedWork W2490914975 @default.
• W3174842118 hasVolume "109" @default.
• W3174842118 isParatext "false" @default.
• W3174842118 isRetracted "false" @default.
• W3174842118 magId "3174842118" @default.
• W3174842118 workType "article" @default.